Reviva Pharmaceuticals Holdings, Inc. is a late stage pharmaceutical company that discovers, develops, and seeks to commercialize next generation therapeutics for diseases representing significant unmet medical needs. The company focuses its pipeline on central nervous system, inflammatory, and cardiometabolic conditions. It uses a chemical genomics driven technology platform and proprietary chemistry to create new drug candidates. Its current pipeline includes two…
Reviva Pharmaceuticals Holdings, Inc. is a late stage pharmaceutical company that discovers, develops, and seeks to commercialize next generation therapeutics for diseases representing significant unmet medical needs. The company focuses its pipeline on central nervous system, inflammatory, and cardiometabolic conditions. It uses a chemical genomics driven technology platform and proprietary chemistry to create new drug candidates. Its current pipeline includes two proprietary compounds, brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in house. The company has secured composition of matter patents for brilaroxazine and RP1208 in the United States, Europe, and several other jurisdictions.
Reviva Pharmaceuticals Holdings, Inc. has not generated any revenue from the sale of products to date. As a clinical stage biopharmaceutical firm, its primary activities involve research, development, and clinical trials of its drug candidates rather than commercial sales. The company expects to generate revenue only after obtaining regulatory approval and successfully bringing its therapies to market. Until such approval is achieved, it finances its operations through equity offerings, debt financing, and collaboration agreements.
Within the pharmaceutical industry, Reviva Pharmaceuticals Holdings, Inc. competes with both large multinational corporations and specialized biotechnology firms that are developing treatments for schizophrenia, bipolar disorder, depression, and related central nervous system disorders. Its competitive advantages include a proprietary chemical genomics platform that enables rapid identification of novel chemical entities, a robust patent portfolio covering its lead candidates, and orphan drug designations for brilaroxazine in pulmonary arterial hypertension and idiopathic pulmonary fibrosis. The company’s focus on multiple indications for a single molecule also provides potential efficiencies in development and marketing.
Although the company currently does not have commercial sales, its intended customers are patients suffering from psychiatric and neurologic disorders, as well as the healthcare providers and institutions that treat them. These include hospitals, psychiatric clinics, and specialty care centers that prescribe antipsychotic and antidepressant therapies. Should its drug candidates receive approval, the company expects to serve these groups through traditional pharmaceutical distribution channels.